Kymera Therapeutics (NASDAQ:KYMR) received U.S. Food and Drug Administration Fast Track designation for its experimental treatment for moderate-to-severe eosinophilic asthma, a move that could accelerate the path to market for the first-in-class oral therapy.
The drug, known as KT-621, targets the STAT6 protein, a key driver of the inflammation that underlies both asthma and various allergic conditions.
The designation is designed to speed up the development and review of drugs for serious conditions that fill an unmet medical need.
KT-621 is a small-molecule degrader, a relatively new class of medicine that works by tagging specific disease-causing proteins for destruction by the body’s own recycling system.
Unlike current standard-of-care biologics for severe asthma, which must be injected, KT-621 is designed to be taken once daily as a pill.
The STAT6 protein is a central mediator in the signaling of IL-4 and IL-13, two cytokines that are critical to the type 2 inflammatory response.
By degrading the protein itself rather than just blocking its receptor, Kymera aims to provide a more comprehensive blockade of the pathway with the convenience of an oral dosage form.
Kymera is currently conducting global Phase 2b trials for the compound across two major indications.
The company expects to report topline data from its study in atopic dermatitis—the most common form of eczema—by mid-2027.
Data from the Phase 2b trial in moderate-to-severe eosinophilic asthma is anticipated to follow in late 2027.